Articles From: Aeterna Zentaris Reports Second Quarter 2013 Financial and Operating Results to AETI Reports Profit Up 40% in Second Quarter and 148% for First Half 2013


Aeterna Zentaris Reports Second Quarter 2013 Financial and Operating Results Canada NewsWire All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY , Aug.
Sign-up for Aeterna Zentaris Reports Second Quarter 2013 Financial and Operating Results investment picks
2013/8/8
All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, Aug.
Sign-up for Aeterna Zentaris Reports Second Quarter 2013 Financial and Operating Results investment picks
Aeterna Zentaris Reports Third Quarter 2013 Financial and Operating Results Canada NewsWire All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY , Nov.
Sign-up for Aeterna Zentaris Reports Third Quarter 2013 Financial and Operating Results investment picks
2013/11/5
All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, Nov.
Sign-up for Aeterna Zentaris Reports Third Quarter 2013 Financial and Operating Results investment picks
2014/3/12
QUEBEC CITY , March 12, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its fourth quarter and full-year 2013 financial and operating results after market close on Thursday, March 20, 2014 .
Sign-up for Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014 investment picks
2013/8/1
MONTREAL , Aug.
Sign-up for Aeterna Zentaris to Announce Second Quarter 2013 Financial and Operating Results on August 8, 2013 investment picks
2013/10/29
QUEBEC CITY , Oct.
Sign-up for Aeterna Zentaris to Announce Third Quarter 2013 Financial and Operating Results on November 5, 2013 investment picks
2013/10/29
Aeterna Zentaris to Announce Third Quarter 2013 Financial and Operating Results on November 5, 2013 Canada NewsWire QUEBEC CITY , Oct.
Sign-up for Aeterna Zentaris to Announce Third Quarter 2013 Financial and Operating Results on November 5, 2013 investment picks
2013/8/7
QUÉBEC CITY, Aug.
Sign-up for Aeterna Zentaris to Present at Upcoming Canaccord Genuity Global Growth Conference in Boston investment picks
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York Canada NewsWire QUÉBEC CITY, Aug.
Sign-up for Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York investment picks
2013/8/29
QUÉBEC CITY, Aug.
Sign-up for Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York investment picks
2014/4/1
QUÉBEC CITY, April 1, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California .
Sign-up for Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego investment picks
2014/4/1
Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego Canada NewsWire QUÉBEC CITY, April 1, 2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California .
Sign-up for Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego investment picks
Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer Canada NewsWire QUÉBEC CITY, Feb.
Sign-up for Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer investment picks
All amounts are in U.S. dollars (unless otherwise noted) QUÉBEC CITY, July 31, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the first patient has been recruited and dosed for the Phase 3 ZoptEC ( Zopt arelin doxorubicin in E ndometrial C ancer) trial in women with endometrial cancer resistant to platinum/taxane-based chemotherapy.
Sign-up for Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin (AEZS-108) investment picks
2014/4/9
Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors Canada NewsWire QUÉBEC CITY, April 9, 2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a poster on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, provides rationale for new therapeutic opportunities in oncology with this compound.
Sign-up for Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors investment picks
2014/4/9
QUÉBEC CITY, April 9, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a poster on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, provides rationale for new therapeutic opportunities in oncology with this compound.
Sign-up for Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors investment picks
2014/2/3
Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH Canada NewsWire The session will be held on Tuesday, February 11, 2014 , in Hall A of the Wyndham Hotel in Salzburg .
Sign-up for Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH investment picks
SAN DIEGO , Sept.
Sign-up for Aethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract investment picks
2014/2/26
SAN DIEGO , Feb.
Sign-up for Aethlon Medical® Announces Agreement with DaVita Clinical Research® investment picks
2014/3/10
HOUSTON, March 10, 2014 (GLOBE NEWSWIRE) -- American Electric Technologies, Inc. (Nasdaq:AETI) , a leading supplier of power delivery solutions for the global energy industry, today announced that it has relocated its corporate headquarters to 1250 Wood Branch Park Drive, Suite 600, Houston, TX, 77079.
Sign-up for AETI Announces Relocation to The Energy Corridor investment picks
2014/3/7
HOUSTON, March 7, 2014 (GLOBE NEWSWIRE) -- American Electric Technologies, Inc. (Nasdaq:AETI) , a leading provider of power delivery solutions for the global energy industry, announced today that Chief Executive Officer, Charles Dauber, will present at ROTH Capital Partners 26 th Annual Growth Stock Conference at The Ritz Carlton in Dana Point, CA on Wednesday, March 12, 2014.
Sign-up for AETI CEO to Present at ROTH Capital Partners 26th Annual Growth Stock Conference investment picks
2014/3/4
HOUSTON, March 4, 2014 (GLOBE NEWSWIRE) -- American Electric Technologies, Inc. (Nasdaq:AETI) , a leading supplier of power delivery solutions for the global energy industry, today announced its fourth quarter and fiscal year 2013 financial results.
Sign-up for AETI Reports 2013 Q4 and Fiscal Year Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Aeterna Zentaris Reports Second Quarter 2013 Financial and Operating Results to AETI Reports Profit Up 40% in Second Quarter and 148% for First Half 2013
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity